Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;20(4):355-369.
doi: 10.1080/17435889.2025.2457315. Epub 2025 Jan 28.

Advances in the use of nanotechnology for treating gout

Yi-Zhen Wang  1 , Zi-Xuan Wang  1 , Hong-Jiang Jiang  2 , Li-Hui Ni  1 , Hao Ju  1 , Yan-Chao Wu  1 , Hui-Jing Li  1
Affiliations
Review

Advances in the use of nanotechnology for treating gout

Yi-Zhen Wang et al. Nanomedicine (Lond). 2025 Feb.

Abstract

Gout is a commonly occurring form of inflammatory arthritis caused by persistently elevated levels of uric acid. Its incidence rate rises with the increases of living standards and poor dietary habits, which has a considerable impact on the quality of life of the patients. Although there is a wide assortment of drugs available for the management of gout, the effectiveness and security of these drugs are limited by their poor chemical stability and insufficient targeting. Therefore, development of effective nanomedicine systems to overcome these problems and treat gout becomes a high priority. This review provides a detailed introduction research progress on developing advanced nanomedicines using polymers, hydrogel, nanocapsules, lipids, bionic vesicles, inorganic artificial organelles and electronically controlled conveyor systems carriers to improve gout therapy.

Keywords: Gout; artificial organelles; electronically controlled conveyor systems; gouty arthritis; inorganic nanoparticles; lipid nanoparticles; polymer nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

References

    1. Yip K, Berman J.. What is gout? J Am Med Assoc. 2021;326(24):2541–2541. - PubMed
    1. Kuo C-F, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. - PubMed
    1. Cross M, Ong KL, Culbreth GT, et al. Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021. Lancet Rheumatol. 2024;6(8):e507–e517. - PMC - PubMed
    1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516. - PubMed
    1. Mastalerz L, Trąd G, Szatkowski P, et al. Aspirin hypersensitivity diagnostic index (AHDI): in vitro test for diagnosing of N‐ERD based on urinary 15‐oxo‐ETE and LTE4 excretion. Allergy. 2024:16281. - PMC - PubMed

Publication types

LinkOut - more resources